Synergies of microtissue design, viral transduction and adjustable transgene expression for regenerative medicine.
In the past decade, regenerative medicine has evolved as an interdisciplinary field, integrating expertise from the medical, life- and material-science communities. Recent advances in tissue engineering, gene therapy, gene-function analysis, animal-free drug testing, drug discovery, biopharmaceutical manufacturing and cell-phenotype engineering have capitalized on a core technology portfolio including artificial microtissue design, viral transduction and precise transcription dosing of therapeutic or phenotype-modulating transgenes. We provide a detailed overview on recent progress in these core technologies and comment on their synergistic impact on current and future human therapies.
Kelm
Jens M
JM
Institute of Biotechnology, Swiss Federal Institute of Technology, ETH Hoenggerberg, HPT, CH-8093 Zurich, Switzerland.
Kramer
Beat P
BP
Gonzalez-Nicolini
Valeria
V
Ley
Bettina
B
Fussenegger
Martin
M
D000818:Animals; D005786:Gene Expression Regulation; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D044968:Regenerative Medicine / Q000379:methods*; D023822:Tissue Engineering / Q000379:methods*; D014161:Transduction, Genetic / Q000379:methods; D019076:Transgenes / Q000235:genetics; D014780:Viruses / Q000235:genetics